A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Latest Information Update: 20 Jul 2026
At a glance
- Drugs Antihyperglycaemics (Primary) ; Semaglutide
- Indications Diabetes mellitus; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 16 Jul 2026 Planned End Date changed from 30 Aug 2026 to 17 Nov 2026.
- 16 Jul 2026 Planned primary completion date changed from 30 Apr 2026 to 27 Oct 2026.
- 16 Jul 2026 Status changed from not yet recruiting to recruiting.